The economic burden of smoking extends far beyond healthcare spending — it quietly drains worker productivity and national social security systems in ways that rarely make headlines. A twelve-year analysis of Mexico's largest public insurer reveals just how deeply tobacco's costs are embedded in formal labor markets, with implications for any country where occupational sick leave is publicly subsidized.
Drawing on anonymized records from the Instituto Mexicano del Seguro Social (IMSS) — Latin America's largest insurer — researchers applied smoking-attributable fractions to sick leave data spanning 2010 through 2022. Six major tobacco-linked non-communicable diseases were examined: COPD, lung cancer, acute myocardial infarction, cerebrovascular disease, diabetes, and mental illness. Across the study period, tobacco-attributable sick leave averaged roughly 9,600 events annually out of approximately 32,500 total NCD-related absences — meaning nearly 30% of all major-disease sick leave traced back to smoking. By 2022, the direct institutional cost reached Mx$113.1 million, with broader social costs rising when full salary replacement (rather than the 60% IMSS subsidy) was factored in. Notably, COPD-related absences spiked during the COVID-19 pandemic, while AMI-related leave durations declined substantially over the study window — possibly reflecting improved acute cardiac care.
This research is methodologically rigorous — a 12-year longitudinal record with 1,000 bootstrapped samples to handle uncertainty — but remains observational and institution-specific. The IMSS covers formal-sector workers only, meaning the true national burden, which includes informal labor markets where smoking rates are often higher, is almost certainly underestimated. From a broader perspective, the finding that one peso in every three spent by IMSS on major NCD sick leave is tobacco-attributable powerfully reframes tobacco as a fiscal policy issue, not merely a public health one. For health economists and policymakers in middle-income countries with similar social insurance architectures, this quantification offers a compelling cost-benefit lens for tobacco taxation and cessation investment. The study is confirmatory in spirit but meaningfully advances the economic evidence base for Latin America.